← Back to Clinical Trials
Recruiting NCT03371641

NCT03371641 In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03371641
Status Recruiting
Phase
Sponsor University Hospital, Rouen
Condition Fetal Alcohol Syndrome
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2017-01-27
Primary Completion 2026-03-27

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
ASQ parental questionnaireDevelopment scalesScale of Conners

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2017-01-27 with a primary completion date of 2026-03-27.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to validate that PLGF is a biomarker of cerebral lesions and therefore of secondary developmental disorders and disabilities that will be best diagnosed at 2 and 6 years of age.

Eligibility Criteria

Inclusion Criteria: Mother: * Pregnant woman (monofetal or twin pregnancy, whatever the parity) * Age\> or = to 18 years * Person affiliated to a social security system * Person who read and understood the information form and signed the consent form * Alcohol exposure group Chronic consumption of at least 30 g of alcohol per week or acute consumption of "binge drinking" type during pregnancy (knowing that a unit of 10 g of pure alcohol corresponds to 25 cl of beer 4 ° 5, 10 cl of wine at 12 °, 3 cl of whiskey, 7 cl of Porto ...) * Control group No alcohol consumption during pregnancy * Child Informed parents and written consent signed by the father and mother for the child's participation in this research (unless one of the parents does not have parental authority) Exclusion Criteria: * Female under 18 * Pregnant woman with clinical suspicion of pre-eclampsia and / or HELLP syndrome * Person deprived of liberty by an administrative or judicial decision or protected major subject (under tutorship or curatorship) * Patient participating in another interventional trial or who participated in another interventional trial during pregnancy

Contact & Investigator

Central Contact

POURCHER

✉ cecile.pourcher@chu-rouen.fr

📞 02 32 88 82 65

Frequently Asked Questions

Who can join the NCT03371641 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Fetal Alcohol Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03371641 currently recruiting?

Yes, NCT03371641 is actively recruiting participants. Contact the research team at cecile.pourcher@chu-rouen.fr for enrollment information.

Where is the NCT03371641 trial being conducted?

This trial is being conducted at Rouen, France.

Who is sponsoring the NCT03371641 clinical trial?

NCT03371641 is sponsored by University Hospital, Rouen. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology